---
title: "National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England"
ocid: "ocds-h6vhtk-02ab4a"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ab4a"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02ab4a.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02ab4a.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2021-04-28"
---

# National Framework Agreement for the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-02ab4a

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ab4a)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02ab4a.json)

## Summary

The NHS Commissioning Board (operating as NHS England) has completed a public procurement process for the National Framework Agreement concerning the supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies in the North of England. This procurement is classified under the pharmaceutical products category and encompasses various lots covering specific medications. The framework agreement commenced on 1 April 2021 and is set for a duration of 12 months, with potential extensions, allowing for a total of up to 48 months. The procurement was conducted using an open procedure.

This framework presents significant opportunities for businesses, particularly those involved in the pharmaceutical sector, including manufacturers and suppliers of cytotoxic medicines and monoclonal antibodies. Companies with expertise in aseptic preparation and those that can meet the rigorous standards expected in healthcare delivery would be well-placed to compete. Furthermore, the process allows for involvement from both large enterprises and small and medium-sized enterprises (SMEs), providing a broad range of businesses the chance to contribute to the UK's healthcare supply chain.

## Notice

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. Period of framework agreement: 1 April 2021 to 31 March 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

### Lot Information

Fluorouracil in Elastomeric Devices (Autofuser 2ml/hr) - Lot 25

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Folfusor LV1.5) - Lot 22

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Atezolizumab - Lot 1

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Avastin) - Lot 2

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Zirabev) - Lot 3

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bevacizumab (Aybintio) - Lot 4

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Bleomycin - Lot 5

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Cyclophosphamide Bags - Lot 11

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Obinutuzumab - Lot 33

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Pemetrexed - Lot 38

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fludarabine Bags - Lot 17

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Ganciclovir - Lot 27

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Methotrexate - Lot 31

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Folfusor LV5) - Lot 23

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil Bags - Lot 19

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Bortezomib - Lot 6

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Pertuzumab - Lot 39

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Carboplatin - Lot 7

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Panitumumab - Lot 36

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Vinorelbine - Lot 50

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Folfusor SV2.5) - Lot 21

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Irinotecan - Lot 30

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fludarabine Syringes - Lot 16

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Trastuzumab (Trasimera) - Lot 47

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Autofuser 2.5ml/hr) - Lot 24

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Pembrolizumab - Lot 37

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cetuximab - Lot 8

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Docetaxel - Lot 13

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil Syringes - Lot 18

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Doxorubicin - Lot 14

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Fluorouracil in Elastomeric Devices (Surefuser) - Lot 26

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Cytarabine - Lot 12

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Nivolumab - Lot 32

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cyclophosphamide Syringes - Lot 10

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Trastuzumab (Herzuma) - Lot 44

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Oxaliplatin - Lot 34

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Vinblastine - Lot 48

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Cisplatin - Lot 9

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Gemcitabine - Lot 28

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Vincristine - Lot 49

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Herceptin) - Lot 43

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Ontruzant) - Lot 46

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Epirubicin - Lot 15

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

Rituximab (Truxima) - Lot 42

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Rituximab (Mabthera) - Lot 40

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Rituximab (Rixathon) - Lot 41

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Paclitaxel - Lot 35

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Trastuzumab (Kanjinti) - Lot 45

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Fluorouracil in Elastomeric Devices (Folfusor SV0.5) - Lot 20

NHS National Framework Agreement for the Supply of Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - North of England. The framework agreement will commence on 1 April 2021 for a period of 12 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for the list of purchasing points.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/009177-2021 |
| Notice type | Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 28 Apr 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 18 Mar 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 4 |
| Supplier names | BAXTER HEALTHCARE; ITH PHARMA; QUALASEPT LTD T/A BATH ASU; QUANTUM ASEPTIC SERVICES |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 28 Apr 2021 at 15:29 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/009177-2021

## Notice URLs

- https://ted.europa.eu/udl?uri=TED:NOTICE:506278-2020:TEXT:EN:HTML
- https://www.england.nhs.uk/
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ab4a. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02ab4a.json.